WIRE)–Itamar-Medical, the world’s leader of non-invasive devices for
diagnosis of cardiovascular health, announced achievement of the next milestone
of the international pharmaceutical company, Roche, to further develop the
EndoPAT technology for pre-clinical trials. This is a continuation of the
original announcement from December 2010.
The device developed will enable pharmaceutical companies in
general to potentially integrate EndoPAT into a large number of drug
development projects at a very early drug development stage.
Itamars EndoPAT technology serves as a vital, non-invasive
diagnostic tool for measuring endothelial dysfunction – the early stage of
arteriosclerosis in humans.
“Further to our work with Roche, this continued
development strengthens Itamar-Medical’s strategic direction that the EndoPAT
can support translational medicine a further step towards the important trend
of Personalized Medicine using Companion Diagnostics,” said Dr. Dov Rubin,
President and CEO of Itamar-Medical Ltd.
Dr. Koby Sheffy, Senior Vice President of Technology at
Itamar-Medical added, “This advanced development positions the EndoPAT
technology as a preferred technology in the development of cardiovascular
drugs, from the early animal model stage and over the continued various
development stages with humans.”
About Itamar Medical
Itamar Medical Ltd. is a publicly-traded medical technology company utilizing PAT™ (Peripheral Arterial Tone)
signal technology and applications. The PAT signal is a non-invasive “window”
to both the cardiovascular and autonomic nervous systems. For more information,
Posted by Sean Fenske, Editor-in-Chief, MDT